GO
Loading...

Medicine

More

  • Case closed on vaccine-autism debate: Doctor Wednesday, 4 Feb 2015 | 8:27 AM ET
    Vials of measles, mumps and rubella vaccine are displayed on a counter at a Walgreens Pharmacy on January 26, 2015 in Mill Valley, California.

    The scientific community has thoroughly debunked any association behind autism and vaccination, Dr. Scott Gottlieb tells CNBC.

  • CHICAGO, Feb 4- After successfully treating four Ebola patients last year, Emory University in Atlanta is now leading a government-funded project that will use blood from survivors of the deadly virus to test a novel way of treating infectious disease. The Defense Advanced Research Projects Agency, the Pentagon's elite research arm, has awarded Emory up to...

  • Feb 3- Gilead Sciences Inc on Tuesday said it is offering steeper-than-expected discounts on its hepatitis C drugs to health insurers and other group payers who had complained about the price, and the drugmaker's shares slid more than 5 percent. Gilead executives disclosed the discounts on a conference call after the company said strong sales of the drugs,...

  • Can't force vaccines on people: Aetna CEO Tuesday, 3 Feb 2015 | 5:12 PM ET
    Mark Bertolini, CEO of Aetna at 2015 WEF in Davos, Switzerland.

    Whether to vaccinate is a public health issue, but there are other ways to handle the matter other than mandating it, Aetna's CEO said.

  • Measles cases cost US economy this much Tuesday, 3 Feb 2015 | 4:37 PM ET
    Miami Children's Hospital pediatrician Dr. Amanda Porro, M.D administers a measles vaccination to Sophie Barquin,4, as her mother Gabrielle Barquin and Miami Children's Hospital R.N. Diane Lichtman (R) hold her during a visit to the Miami Children's Hospital on January 28, 2015 in Miami, Florida.

    A measles outbreak to a tiny piece of the American population would drain billions from the U.S. economy, an expert said.

  • Feb 3- The U.S. Food and Drug Administration on Tuesday said it had approved Pfizer Inc's experimental breast cancer drug Ibrance, a regulatory decision that came more than two months earlier than expected. Wall Street has considered the drug, whose chemical name is palbociclib, to be one of the most promising medicines in Pfizer's development pipeline.

  • Gilead announces first dividend  Tuesday, 3 Feb 2015 | 4:13 PM ET

    Gilead is announcing a fourth quarter beat, its first dividend and a stock buyback program, with CNBC's Meg Tirrell.

  • Mandate measles vaccine?  Tuesday, 3 Feb 2015 | 2:54 PM ET

    Should the U.S. government mandate vaccinations? Dr. Devi Nampiaparampil, NYU School of Medicine, and Dr. Jeffrey Singer, Cato Institute, discuss the importance of vaccinations, and respecting the rights of parents.

  • Feb 3- The state of Washington said Tuesday it has established a third poultry quarantine zone after state officials discovered that a flock of about 100 birds in Okanogan County was infected with the avian influenza virus. The Washington State Department of Agriculture adopted an emergency rule on Sunday to establish the new quarantine area, which...

  • Why vaccines can't be a choice: Disease specialist Tuesday, 3 Feb 2015 | 10:14 AM ET
    Miami Children's Hospital pediatrician Dr. Amanda Porro, M.D prepares to administer a measles vaccination to a child at the Miami Children's Hospital on January 28, 2015 in Miami, Florida.

    Dr. Gail Shust, an infectious disease specialist, tells CNBC, "It really is not just a personal choice but a public health issue."

  • Feb 3- Isis Pharmaceuticals Inc's experimental diabetes drug took a longer-than-expected 36 weeks to reduce blood sugar levels in patients with type 2 diabetes. Deutsche Bank's Alethia Young said the data looked less robust that some commonly prescribed treatments and Isis's own experimental glucagon receptor, ISIS-GCGR. Type 2 diabetes is a chronic...

  • Feb 3- Isis Pharmaceuticals Inc said its experimental diabetes drug was effective in reducing the body weight and blood sugar in patients with type 2 diabetes. The drug, ISIS-PTP1B, was tested against a placebo in a mid-stage study comprising 92 type 2 diabetes patients with uncontrolled blood sugar, despite treatment. Type 2 diabetes is a chronic condition...

  • Feb 3- Isis Pharmaceuticals Inc said its experimental diabetes drug was effective in reducing the body weight and blood sugar of patients with type 2 diabetes.

  • Sanofi launches inhaled insulin for diabetics Tuesday, 3 Feb 2015 | 1:00 AM ET

    PARIS, Feb 3- Sanofi launched an inhalable insulin in the United States on Tuesday in a potential boost for its flagging diabetes drug sales and for patient quality of life. Developed by Mannkind Corp, Afrezza will be the only inhalable insulin on the U.S. market, where Sanofi competes with Eli Lilly and Novo Nordisk for sales of traditional injectable insulin.

  • MONROVIA, Feb 2- Liberia began a trial of experimental Ebola vaccines on Monday, involving thousands of volunteers as part of an effort to slow the spread of the deadly haemorrhagic fever and prevent future outbreaks. The epidemic has killed more than 8,900 people in West Africa since it began more than a year ago, overwhelming weak healthcare systems in Guinea,...

  • Feb 2- Ardelyx Inc said chronic kidney disease patients treated with its kidney drug experienced higher-than-expected levels of diarrhea in a mid-stage study. The drug, Tenapanor, being co-developed with AstraZeneca PLC, however, met the main goal of "significantly" reducing phosphate levels in patients who were on dialysis. Ardelyx licensed the drug to...

  • MONROVIA, Feb 2- Liberia began a trial of experimental Ebola vaccines on Monday, involving thousands of volunteers as part of an effort to slow the spread of the deadly haemorrhagic fever and prevent future outbreaks. The epidemic has killed more than 8,800 people in West Africa since it began more than a year ago, overwhelming weak healthcare systems in Guinea,...

  • Feb 2- The U.S. Food and Drug Administration approved a drug developed by Eli Lilly and Co and Boehringer Ingelheim Pharmaceuticals Inc to improve blood sugar control in type-2 diabetes patients, the companies said. "Half of people with type-2 diabetes do not achieve recommended blood sugar control, making new treatment options more important than ever," Eli...

  • Feb 2- The U.S. Food and Drug Administration approved a drug developed by Eli Lilly and Co and privately held Boehringer Ingelheim Pharmaceuticals Inc to improve blood sugar control in type-2 diabetes patients, the companies said.

  • Feb 2- Ardelyx Inc said its experimental drug "significantly" decreased phosphate levels in chronic kidney disease patients who were on dialysis. Ardelyx licensed the drug to AstraZeneca in October 2012. Under the terms of the agreement, AstraZeneca handles the development costs for tenapanor, while Ardelyx runs the trials.